Advertisement

International Journal of Colorectal Disease

, Volume 22, Issue 2, pp 183–189 | Cite as

Rare tumors of the colon and rectum: a national review

  • Hakjung Kang
  • Jessica B. O’Connell
  • Michael J. Leonardi
  • Melinda A. Maggard
  • Marcia L. McGory
  • Clifford Y. KoEmail author
Original Article

Abstract

Background

Most literature available on rare colorectal cancer (CRC) is from case series reports. This population-based evaluation is the first comprehensive look at four rare histologic types of CRC, allowing comparisons with the more common adenocarcinoma for clinical and pathological features and survival rates.

Materials and ethods

All patients diagnosed with carcinoid (n=2,565), malignant lymphoma (n=955), non-carcinoid neuroendocrine (n=455), squamous cell (n=437), and adenocarcinoma (n=164,638) in SEER cancer database (1991–2000) were analyzed. Evaluation of age-adjusted incidence rate, stage at presentation, and 5-year relative survival were determined for each histologic subtype.

Results

All rare histologic subtypes had younger mean age than adenocarcinomas (70 years; p<0.05). Lymphoma was more common in males (65.1%; P<0.01). Incidence rates in 2000 per million were: carcinoid 10.6, lymphoma 3.5, neuroendocrine 2.0, squamous 1.9, and adenocarcinoma 496.3. The annual percent change in incidence for each rare tumor increased significantly during the 10 years (range: 3.1–9.4%, p<0.05), except squamous cell carcinoma (5.9%, p>0.05). Squamous (93.4%) and carcinoid (73.7%) tumors occurred more often in the rectum; lymphoma (79.0%), neuroendocrine (70.8%), and adenocarcinoma (70.1%) occurred more often in the colon (P<0.01). Carcinoids presented at earlier stage (localized/regional, 90.5%) more often than adenocarcinoma (80.6%; p<0.01), but squamous cell (82.1%; p=0.50), lymphoma(70.6%; p<0.01), and neuroendocrine (37.8%; p<0.01) presented at earlier stage similarly or less often than adenocarcinoma. Relative 5-year survival rate was highest for carcinoid (91.3%), and lowest for neuroendocrine tumors (21.4%).

Conclusion

This study provides the first population-based analysis of the epidemiology, tumor characteristics, and survival rates for rare CRC.

Keywords

Colorectal SEER Carcinoid Lymphoma Rare tumor 

Notes

Acknowledgement

This study was funded in part by a grant from the American Society of Colon and Rectal Surgeons (ASCRS) Research Foundation.

References

  1. 1.
    American Cancer Society (2004) Cancer facts and figures 2004. The American Cancer Society. No 5008.04. Surveillance Research, New YorkGoogle Scholar
  2. 2.
    Gloria Niehans: Neoplasms of the large and small intestine. Available at: http://www.lamp.med.umn.edu
  3. 3.
    DiSario JA, Burt RW, Kendrick ML et al (1994) Colorectal cancers of rare histologic types compared with adenocarcinomas. Dis Colon Rectum 37:1277–1280PubMedCrossRefGoogle Scholar
  4. 4.
    Human colorectal cancer. The Mouse Models of Human Cancers Consortium (MMHCC) cancer models database on the EMICE website provided by National Cancer Institute (NCI); Available at: http://emice.nci.nih.gov/emice
  5. 5.
    Bernick PE, Klimstra DS, Shia J et al (2004) Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum 47:163–169PubMedCrossRefGoogle Scholar
  6. 6.
    Grabowski P, Schonfelder J, Ahnert-Hilger G et al (2002) Expression of neuroendocrine markers: a signature of human undifferentiated carcinoma of the colon and rectum. Virchows Arch 441:256–263PubMedCrossRefGoogle Scholar
  7. 7.
    Shebani KO, Souba WW, Finkelstein DM et al (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 229:815–821; Discussion 822–823PubMedCrossRefGoogle Scholar
  8. 8.
    Koch P, del Valle F, Berdel WE et al (2001) Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma—results of the prospective GermanMulticenter Study GIT NHL 01/92. J Clin Oncol 19:3874–3883PubMedGoogle Scholar
  9. 9.
    Radaszkiewicz T, Dragosics B, Bauer P (1992) Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology 102:1628–1638PubMedGoogle Scholar
  10. 10.
    Surveillance Epidemiology and End Results (SEER) Program Public-Use Data (1973–1999), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission. Available at: http://www.seer.cancer.gov/about
  11. 11.
    Moore DS, McCabe GP (1998) Introduction to the practice of statistics. W.H. Freeman and Company, New YorkGoogle Scholar
  12. 12.
    Maggard MA, O’Connell JB, Ko CY (2004) Updated population-based review of carcinoid tumors. Ann Surg 240:117–122PubMedCrossRefGoogle Scholar
  13. 13.
    Crocetti E, Paci E (2003) Malignant carcinoids in the USA, SEER 1992–1999. An epidemiological study with 6830 cases. Eur J Cancer Prev 12:191–194PubMedCrossRefGoogle Scholar
  14. 14.
    Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934–959PubMedCrossRefGoogle Scholar
  15. 15.
    Nakamura S, Matsumoto T, Iida M (2003) Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer 97:2462–2473PubMedCrossRefGoogle Scholar
  16. 16.
    Koh PK, Horsman JM, Radstone CR et al (2001) Localised extranodal non-Hodgkin’s lymphoma of the gastrointestinal tract: Sheffield Lymphoma Group experience (1989–1998). Int J Oncol 18:743–748PubMedGoogle Scholar
  17. 17.
    Cartwright R, Brincker H, Carli PM et al (1999) The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 35:627–633PubMedCrossRefGoogle Scholar
  18. 18.
    Devesa SS, Fears T (1992) Non-Hodgkin’s lymphoma time trends: United States and international data. Cancer Res 52(19 Suppl):5432s–5440sPubMedGoogle Scholar
  19. 19.
    Saha S, Hoda S, Godfrey R et al (1989) Carcinoid tumors of the 44-year experience. South Med J 82:1501–1505PubMedGoogle Scholar
  20. 20.
    Jinnai D, Iwasa Z, Watanuki T (1983) Malignant lymphoma of the large intestine-operative results in Japan. Jpn J Surg 13:331–336PubMedCrossRefGoogle Scholar
  21. 21.
    Shepherd NA, Hall PA, Coates PJ, Levison DA (1988) Primary malignant lymphoma of the colon and rectum. A histopathological and immunohistochemical analysis of 45 cases with clinicopathological correlations. Histopathology 12:235–252PubMedGoogle Scholar
  22. 22.
    Richards MA (1986) Lymphoma of the colon and rectum. Postgrad Med J 62:615–620PubMedCrossRefGoogle Scholar
  23. 23.
    Berardi RS, Chen HP, Lee SS (1986) Squamous cell carcinoma of the colon and rectum. Surg Gynecol Obstet 163:493–496PubMedGoogle Scholar
  24. 24.
    Schneider TA 2nd, Birkett DH, Vernava AM 3rd (1992) Primary adenosquamous and squamous cell carcinoma of the colon and rectum. Int J Colorectal Dis 17:144–147CrossRefGoogle Scholar
  25. 25.
    Frizelle FA, Hobday KS, Batts KP et al (2001) Adenosquamous and squamous carcinoma of the colon and upper rectum: a clinical and histopathologic study. Dis Colon Rectum 44:341–346PubMedCrossRefGoogle Scholar
  26. 26.
    Cagir B, Nagy MW, Topham A et al (1999) Adenosquamous carcinoma of the colon, rectum, and anus: epidemiology, distribution, and survival characteristics. Dis Colon Rectum 42:258–263PubMedCrossRefGoogle Scholar
  27. 27.
    North American Association of Central Cancer Registries. Available at: http://www.naaccr.org
  28. 28.
    Virnig BA, Warren JL, Cooper GS et al (2002) Studying radiation therapy using SEER-Medicare-linked data. Med Care 40(8 Suppl):IV49–IV54Google Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Hakjung Kang
    • 1
    • 2
  • Jessica B. O’Connell
    • 2
    • 3
  • Michael J. Leonardi
    • 2
  • Melinda A. Maggard
    • 2
  • Marcia L. McGory
    • 2
  • Clifford Y. Ko
    • 2
    • 3
    • 4
    Email author
  1. 1.Department of SurgeryDaehang HospitalSeoulSouth Korea
  2. 2.UCLA Center for Surgical Outcomes and QualityDavid Geffen School of Medicine at University of California, Los AngelesLos AngelesUSA
  3. 3.Department of SurgeryVA Greater Los Angeles Healthcare SystemLos AngelesUSA
  4. 4.Department of SurgeryDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations